Review anchor
Dual specificity mitogen-activated protein kinase kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Dual specificity mitogen-activated protein kinase kinase 4
CHEMBL2897
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity mitogen-activated protein kinase kinase 4 as ChEMBL target CHEMBL2897, mapped to UniProt P45985. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2897
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P45985
Dual specificity mitogen-activated protein kinase kinase 4
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Dual specificity mitogen-activated protein kinase kinase 4 matters
Dual specificity mitogen-activated protein kinase kinase 4 is reviewed as Dual specificity mitogen-activated protein kinase kinase 4 (UniProt P45985); the current evidence base includes 9 approved drugs, 726 compounds, and 250 assays, with lead potency reaching pChEMBL 8.8.
Protein context
Dual specificity mitogen-activated protein kinase kinase 4
Dual specificity mitogen-activated protein kinase kinase 4 Sequence length is 399 aa.
Review this target as Dual specificity mitogen-activated protein kinase kinase 4, mapped to UniProt P45985. Sequence length is 399 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P45985
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 9 approved drugs, 726 compounds, and 250 assays for this target. The dominant activity type is IC50. CHEMBL4865410 is the current potency anchor at pChEMBL 8.8.
Use CHEMBL4865410 as the tractability anchor when discussing potency (pChEMBL 8.8).
Activity source · ChEMBL 36 via Core Engine
9 approved
pChEMBL 8.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Dual specificity mitogen-activated protein kinase kinase 4 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P45985, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
726
Total Compounds
250
Total Assays
9
Approved Drugs
IC50: 345.0, KD: 225.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4865410
|
8.8 | Kd | — |
|
|
No preferred name
CHEMBL4798975
|
8.8 | Kd | — |
|
|
No preferred name
CHEMBL603469
|
8.4 | Kd | Clinical |
|
|
No preferred name
CHEMBL4790247
|
7.5 | IC50 | — |
|
|
No preferred name
CHEMBL4758063
|
7.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TOVORAFENIB
CHEMBL3348923
|
2024 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header